Clinical Trial Detail

NCT ID NCT04102098
Title A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

hepatocellular carcinoma

Therapies

Atezolizumab + Bevacizumab

Age Groups: adult senior

No variant requirements are available.